کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3000798 | 1180345 | 2008 | 10 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
NF-κBA1chsCRPSAAPAI-1HDL-CPPARLDL-CMCP-1ICAM-1High-sensitivity CRP - CRP حساسیت بالاMyocardial infarction - آنفارکتوس میوکاردinterleukin - اینترلوکینtumor necrosis factor α - تومور نکروز عامل αDiabetes mellitus - دیابت قندیRac-1 - راک 1Ras-related C3 botulinum toxin substrate 1 - زیر بغل سم بوتولینوم C3 مرتبط با ریز 1serum amyloid A - سرم آمیلوئید AMIF - شهرMacrophage migration inhibitory factor - عامل مهارکننده مهاجرت ماکروفاژTNF-α - فاکتور نکروز توموری آلفاnuclear factor κB - فاکتور هسته ای κBhigh-density lipoprotein cholesterol - لیپوپروتئین پرچگالی یا اچدیالplasminogen activator inhibitor 1 - مهار کننده فعال کننده پلاسمینوژن 1Intercellular adhesion molecule 1 - مولکول چسبندگی بین سلولی 1Glycated hemoglobin - هموگلوبین گلیکوزیلهmonocyte chemoattractant protein 1 - پروتئین cheoattractant monocyte 1C-reactive protein - پروتئین واکنشی سیCRP - پروتئین واکنشی سی یا سی. آر. پی Low-density lipoprotein cholesterol - کلسترول لیپوپروتئین با چگالی کمperoxisome proliferator-activated receptor - گیرنده فعال فعال پروکسیوم
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Type 2 diabetes mellitus (DM) increases the risk of cardiovascular disease, a major cause of morbidity and mortality. Central to type 2 DM is insulin resistance, a proinflammatory, hypercoagulable state that predisposes patients to develop cardiovascular disease and that is associated with risk factors for atherosclerosis including dyslipidemia, hypertension, inflammation, and altered hemostasis. Atherosclerosis is recognized as a chronic inflammatory disease of the arteries. C-reactive protein (CRP) is an acute-phase response protein that is considered both a marker of inflammation and a predictor of cardiovascular events including myocardial infarction, stroke, peripheral arterial disease, and sudden cardiac death. Evidence indicates that CRP has a direct proatherogenic effect through up-regulation of angiotensin II type 1 receptors and through the stimulation of other proinflammatory factors. Patients with type 2 DM tend to have higher CRP concentrations than do those without it, suggesting an increased role of inflammation in the accelerated atherosclerosis seen in these patients. Reducing CRP concentrations through lifestyle changes or pharmacotherapeutics could have clinical benefit; long-term studies are needed to determine whether reductions in CRP concentrations translate into improved cardiovascular outcomes. Because glucose and lipid levels as well as CRP concentrations are often elevated in patients with type 2 DM, an agent that positively affects multiple cardiovascular risk factors would be most beneficial. This article reviews available data on antidiabetic and antihyperlipidemic agents that reduce CRP concentrations in addition to their primary effect of lowering glucose or lipid levels.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mayo Clinic Proceedings - Volume 83, Issue 3, March 2008, Pages 333-342
Journal: Mayo Clinic Proceedings - Volume 83, Issue 3, March 2008, Pages 333-342
نویسندگان
Paresh MBBS, DPhil, FRCP,